Relay Therapeutics Started Phase 3 Zovegalisib Trial
The drug candidate, a PI3Ka inhibitor for breast cancer, reached its final clinical testing stage this week.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you believe pharmaceutical companies are prioritizing the development of enough new cancer treatment options?
Relay Therapeutics has initiated a Phase 3 clinical trial for its drug candidate zovegalisib, an inhibitor targeting PI3Ka-driven breast cancer. The milestone follows the successful development of the compound using X-Chem's DNA-encoded library platform.
Why it matters
This advancement moves a targeted oncology treatment closer to potential clinical use by addressing specific phosphoinositide 3-kinase alpha mutations. The project highlights the utility of DNA-encoded library screening in accelerating the pipeline for complex mutant-selective drug candidates.
Zovegalisib functions as a selective inhibitor for phosphoinositide 3-kinase alpha (PI3Ka), a protein involved in cell growth that is frequently mutated in cancer. The candidate is distinguished by its use of a novel allosteric binding site—a regulatory site distinct from the active catalytic site—to achieve greater mutant selectivity.
The players
Relay Therapeutics
A biotechnology firm that integrates structural biology and machine learning to build an oncology-focused drug pipeline.
X-Chem
A Waltham-based research company specializing in DNA-encoded chemical library technology for small-molecule drug discovery.
The details
The drug candidate was identified using a DNA-encoded chemical library, a research method where millions of small molecules are tagged with unique DNA sequences to allow for high-throughput screening against biological targets. By targeting a novel allosteric binding site, zovegalisib aims to inhibit PI3Ka activity more precisely in cancerous cells while potentially sparing healthy tissue. This approach is intended to overcome the toxicity limitations often associated with pan-PI3K inhibitors.
Timeline
September 22, 2026: X-Chem announced the milestone achievement linked to the trial start.
The Tech Race
The transition of zovegalisib into Phase 3 trials places Relay Therapeutics at the forefront of the race to deliver mutant-selective PI3Ka inhibition for oncology patients. This milestone positions the company ahead of broader, less-selective inhibitors that have historically faced challenges with systemic toxicities.
This development represents a critical step for breast cancer patients who may eventually benefit from a more targeted, selective therapy. As the trial progresses, clinicians and researchers will be watching for efficacy and safety results that define the clinical potential of this drug.
The takeaway
The move to Phase 3 signals that zovegalisib has passed significant safety and efficacy hurdles in earlier studies. Stakeholders should now monitor for future trial data releases, which will determine if the compound succeeds in the clinic where less selective inhibitors have previously failed.
Further reading
For more on the current landscape of oncology drug development, explore our Biotech section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe pharmaceutical companies are prioritizing the development of enough new cancer treatment options?
